Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump

Journal of Translational Medicine, Ausgabe 2021


The use of extracorporeal membrane oxygenation (ECMO) in adult patients has been increasing rapidly in recent years [ 1]. ECMO therapy has become an established alternative as a rescue therapy in the treatment of severe forms of the acute respiratory distress syndrome (ARDS) with promising case series of extracorporeal CO 2 removal (ECCO 2R) in chronic obstructive pulmonary disease (COPD) [ 2– 4]. ECMO use in neonatal or pediatric patients, or the use for ECCO 2R, were considered the key low-flow applications in this study [ 5]. The use of ECMO in children with a weight below 10 kg increased on average by 2.2 % per year between 2011 and 2016. The predominant use of roller pumps switched to centrifugal pumps during this time period [ 6].

Centrifugal blood pumps as central elements of ECMO therapy provide good results in the high-flow operating ranges of 4 L/min–8 L/min of blood flow. However, during low-flow applications, i.e. neonatal or pediatric ECMO or ECCO 2R, the operating ranges are markedly lower at 0.5 L/min–2 L/min. These low-flow operating points contribute to adverse events such as increased hemolysis, platelet activation and bleeding complications [ 7, 8]. Furthermore, this may be a particularly important issue in vulnerable pediatric patients, where blood trauma should be carefully avoided [ 6, 9– 14].

Fortsetzung: https://www.springermedizin.de/hemolysis-at-low-blood-flow-rates-in-vitro-and-in-silico-evaluat/18735404?searchResult=3.Medizintechnik&searchBackButton=true&fulltextView=true&abEvent=detailLink


Resuscitec GmbH
Engesserstraße 4
D-79108 Freiburg


Sie erhalten das Presseclipping der Resuscitec GmbH aufgrund Ihrer Beziehung zu unserem Unternehmen. Wir verarbeiten Ihre Daten auf Grundlage unseres berechtigten Interesses zum Zweck der persönlichen Ansprache und zum Versand unseres Presseclippings. Verantwortlich für die Datenverarbeitung ist die Resuscitec GmbH. Weitere Informationen zum Datenschutz finden Sie in unseren Datenschutzhinweisen. Sie können der Verarbeitung Ihrer personenbezogenen Daten für den Versand des Presseclippings jederzeit formlos widersprechen.


Aus urheberrechtlichen Gründen dürfen die Artikel weder in digitaler noch ausgedruckter Form an Dritte weitergegeben werden. Sie sind nur zum persönlichen Gebrauch bestimmt, der Aufbau einer Datenbank mit digitalisierten Artikeln ist nicht erlaubt.